A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness
American Journal of Physiology-Lung Cellular and Molecular Physiology · 2024
DOI: 10.1152/ajplung.00295.2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Lung Cellular and Molecular Physiology, 2024. Verfasst von Thayse R Brüggemann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass…. Hauptthemen laut MEDLINE: Interleukin-23, Pneumonia, Allergens. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), Pieris Pharmaceuticals (Pieris).
Abstract (Originalsprache)
This is the first report of an Anticalin protein engineered to neutralize IL-23 (AcIL-23). Airway administration of AcIL-23 in mice regulated allergen-driven airway inflammation, mucous cell metaplasia, and methacholine-induced airway hyperresponsiveness. In mixed granulocytic allergic lung inflammation, immune regulation of IL-23 was broader than neutralization of either IL-17 or IL-5.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.
- Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.
ORCID-Profile: Thayse R Brüggemann, Nandini Krishnamoorthy, Matthias Hagner, Thomas Jaquin, Luciana P Tavares, Bruce D Levy
Förderung
- NHLBI NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- Pieris Pharmaceuticals (Pieris)
Zitieren
APA
Brüggemann, T. R., Krishnamoorthy, N., Hagner, M., Matschiner, G., Jaquin, T., Tavares, L. P., Peh, H. Y., & Levy, B. D. (2024). A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness. American Journal of Physiology-Lung Cellular and Molecular Physiology. https://doi.org/10.1152/ajplung.00295.2023
Vancouver
Brüggemann TR, Krishnamoorthy N, Hagner M, Matschiner G, Jaquin T, Tavares LP, et al. A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2024. doi:10.1152/ajplung.00295.2023
BibTeX
@article{Brggemann2024,
author = {Brüggemann, Thayse R and Krishnamoorthy, Nandini and Hagner, Matthias and Matschiner, Gabriele and Jaquin, Thomas and Tavares, Luciana P and Peh, Hong Yong and Levy, Bruce D},
title = {A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness},
journal = {American Journal of Physiology-Lung Cellular and Molecular Physiology},
year = {2024},
doi = {10.1152/ajplung.00295.2023}
}
EUVIMED